← All trials
NCT04561219
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2020
- Primary completion
- Oct 2, 2020
- Completion date
- Oct 2, 2020
- First posted
- Sep 23, 2020
- Last posted
- Oct 28, 2020
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of Rio de JaneiroLead sponsor
- Government of BrazilCollaborator
- Rio de Janeiro State UniversityCollaborator
- Federal University of Rio de JaneiroReponsible party - principal investigator
- Federal University of Rio de JaneiroStudy chair
- Federal University of Rio de JaneiroOverall official - principal investigator
- Hospital Geral de FortalezaCollaborator
- ATCGenCollaborator
- Complexo Hospitalar do Trabalhador de CuritibaCollaborator
- Complexo Hospitalar Municipal de São Caetano do SulCollaborator
- Financiadora de Estudos e ProjetosCollaborator
- Hospital Central da Aeronáutica, Rio de JaneiroCollaborator
- Hospital da Força Aérea do GaleãoCollaborator
- Federal University of PernambucoCollaborator
- Hospital das Clínicas Luzia de Pinho MeloCollaborator
- Hospital das Forças Armadas, BrazilCollaborator
- Hospital de Força Aérea de São PauloCollaborator
- Hospital Eduardo de MenezesCollaborator
- Hospital Estadual de Doenças Tropicais Dr Anuar AuadCollaborator
- Hospital Geral de São Mateus Dr Manoel BifulcoCollaborator
- Hospital Municipal de Barueri Dr Francisco MoranCollaborator
- Hospital Naval Marcilio DiasCollaborator
- Hospital Regional da Asa Norte, BrazilCollaborator
- Hospital Regional de Sorocaba Dr Adib Domingos JateneCollaborator
- Mater Dei Hospital, BrazilCollaborator
- National Research Council, BrazilCollaborator
- Santa Casa de Misericórdia de Belo HorizonteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.